NCT06449586View on ClinicalTrials.gov

CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

NARecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions
Hematologic Malignancy
Interventions
DRUG

Letermovir

letermovir stops when CMI\>1.5

Trial Locations (5)

Unknown

RECRUITING

Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Wuhan

RECRUITING

Ruijin Hospital of Shanghai Jiaotong University, Shanghai

RECRUITING

The First Hospital of Zhejiang University School of Medicine, Hangzhou

RECRUITING

Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai

RECRUITING

Shanghai Liquan Hospital, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER